Double click on photo to enlarge.

Prof. Stuart Ralston, Chair of the Meeting Programme Committee presenting Prof. Juliet Compston with the IBMS John G. Haddad Jr. Award

For outstanding contributions by an IBMS member to clinical research in bone and mineral metabolism, that have led to significant changes in understanding of physiology or disease, or to changes in disease management or prevention.

Award Winners

2009 Juliet Compston, M.D.
(Cambridge, UK) Presented in
Sydney, Australia in March, 2009

Juliet Compston receives IBMS John G. Haddad, Jr. Award
March 30, 2009

Professor Juliet Compston, Board member of the International Osteoporosis Foundation (IOF) and the International Bone and Mineral Society (IBMS), has been awarded the prestigious IBMS John G. Haddad, Jr. Award. The Award was presented during the 2nd Joint Conference of the International Bone & Mineral Society and the Australian & New Zealand Bone & Mineral Society, held in Sydney, Australia from March 21 to 25, 2009.

The IBMS John G. Haddad, Jr. Award recognises outstanding contributions to clinical research in bone and mineral metabolism that have led to significant changes in understanding of physiology or disease, or to changes in disease management or prevention.

Juliet Compston is Professor of Bone Medicine and Honorary Consultant Physician at Cambridge University School of Clinical Medicine. She has published more than 300 papers in the field of metabolic bone disease and has a particular interest in the cellular and structural pathophysiology of bone loss associated with osteoporosis and the effects of drugs on these changes. Research interests also include the effects of glucocorticoids in bone, the role of megakaryocytes in bone remodeling and secondary osteoporosis associated with liver transplantation and with cystic fibrosis.

In addition to her clinical and research activities, Professor Compston is Chair of the EU Osteoporosis Consultation Panel, serves as a Trustee of the Medical Board of the National Osteoporosis Society (NOS), and is a member of the MHRA Expert Advisory Group on Women’s Health and of the Osteoporosis Guidelines Development Group for the National Institute of Clinical Excellence (NICE). She is an Associate Editor of the Journal of Bone and Mineral Research and serves on the editorial board of Bone, Osteoporosis International and the Journal of Clinical Endocrinology and Metabolism.

www.ciaomed.org/articles.cfm?articleID=1285 Published on: 5/2/2007

Juliet Compston, MD, FRCP, of the University of Cambridge School of Clinical Medicine and Addenbrooke's National Health Service Trust, in Cambridge, United Kingdom, points out in an accompanying editorial2 that "although a direct comparison with other treatments cannot be made in the absence of head-to-head studies of fracture outcome, the magnitude of effect appears to be at least similar to and possibly better than (in the case of vertebral fractures) that reported for other interventions."

There is a definite niche for this drug, she writes. "Intravenous zoledronic acid may be particularly appropriate in women who get admitted to the hospital with a fracture (especially a hip fracture) for whom the first infusion could be given during their hospital stay, " she writes.

www.ecommunity.com/news/healthstory.aspx?id=628322 Published on: 6/9/2009

The results support the case against routine monitoring during the early years of treatment, according to an accompanying editorial by Juliet Compston, professor of bone medicine at the University of Cambridge, in England. She said that when changes in bone mineral density are used to monitor treatment, people may be given inappropriate advice.

"Routine monitoring of bone mineral density during the first few years of antiresorptive treatment cannot be justified because it may mislead patients, lead to inappropriate management decisions and waste scarce health care resources," she concluded.

www.nice.org.uk/guidance/index.jsp?action=article&o=402 Published on: 3/1/2008

Professor Juliet Compston, Professor of Bone Medicine, University of Cambridge School of Clinical Medicine and Addenbrooke's NHS Trust - clinical specialist nominated by the Royal College of Physicians

www.cuh.org.uk/addenbrookes/news/2009/may/prof_compston Published on: 5/19/2009
 
Professor Juliet Compston has won the prestigious International Bone and Mineral Society John G Haddad Jr Award, which recognises outstanding contributions to clinical research in bone and mineral metabolism.

Juliet Compston is Professor of Bone Medicine and Honorary Consultant Physician. She has published more than 300 papers in the field of metabolic bone disease.

In addition to her clinical and research activities, Prof Compston is Chair of the EU Osteoporosis Consultation Panel, serves as a Trustee of the Medical Board of the National Osteoporosis Society, and a board member of the International Osteoporosis Foundation and International Bone and Mineral Society.